RE:RE:RE:AstraZeneca's ADC disappoints - on severe adverse eventsPfizer's enfortumab vedotin, sold under the brand name Padcev, is an antibody-drug conjugate currently used for the treatment of urothelial cancer in combination with the checkpoint inhibitor pembrolizumab ( Keytruda).
The antibody-drug conjugate (ADC) Padcev does not have a chemotherapy payload which consequently sets up this category of ADCs for the addition of ONCY's pelareorep in combination with a PD-L1 immune checkpoint inhibitor, such as keytruda or tecentriq, for example.